AU2002213878A1 - Use of erythropoietin and the derivatives of the same for treating schizophrenia and related psychoses - Google Patents

Use of erythropoietin and the derivatives of the same for treating schizophrenia and related psychoses

Info

Publication number
AU2002213878A1
AU2002213878A1 AU2002213878A AU1387802A AU2002213878A1 AU 2002213878 A1 AU2002213878 A1 AU 2002213878A1 AU 2002213878 A AU2002213878 A AU 2002213878A AU 1387802 A AU1387802 A AU 1387802A AU 2002213878 A1 AU2002213878 A1 AU 2002213878A1
Authority
AU
Australia
Prior art keywords
erythropoietin
derivatives
same
treating schizophrenia
related psychoses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002213878A
Inventor
Hannelore Ehrenreich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2002213878A1 publication Critical patent/AU2002213878A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2002213878A 2000-09-04 2001-09-04 Use of erythropoietin and the derivatives of the same for treating schizophrenia and related psychoses Abandoned AU2002213878A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10043457A DE10043457A1 (en) 2000-09-04 2000-09-04 Processes for treating schizophrenia and related psychoses, and using erythropoietin or erythropoietin derivatives to treat schizophrenia and related psychoses
DE10043457.6 2000-09-04
PCT/EP2001/010198 WO2002020031A2 (en) 2000-09-04 2001-09-04 Use of erythropoietin and the derivatives of the same for treating schizophrenia and related psychoses

Publications (1)

Publication Number Publication Date
AU2002213878A1 true AU2002213878A1 (en) 2002-03-22

Family

ID=7654867

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002213878A Abandoned AU2002213878A1 (en) 2000-09-04 2001-09-04 Use of erythropoietin and the derivatives of the same for treating schizophrenia and related psychoses

Country Status (10)

Country Link
US (1) US20040009912A1 (en)
EP (1) EP1315515B1 (en)
JP (1) JP2004522696A (en)
AU (1) AU2002213878A1 (en)
CY (1) CY1107287T1 (en)
DE (2) DE10043457A1 (en)
DK (1) DK1315515T3 (en)
ES (1) ES2296819T3 (en)
PT (1) PT1315515E (en)
WO (1) WO2002020031A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
US9988427B2 (en) 2005-05-13 2018-06-05 Charite Universitaetsmedizen-Berlin Erythropoietin variants
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
RU2484836C2 (en) * 2011-09-21 2013-06-20 Александр Иванович Воронов Method of treating schizophrenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
JP3156236B2 (en) * 1991-09-30 2001-04-16 雪印乳業株式会社 Remedies for improving memory impairment
DE19857609A1 (en) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Use of erythropoietin for the treatment of human cerebral ischemia
BR0009737A (en) * 1999-04-13 2003-01-14 Kenneth S Warren Lab Pharmaceutical composition, pharmaceutical kit with one or more containers, methods for protecting a mammal from a pathology resulting from excitable tissue injury, for enhancing the function of normal or abnormal excitable tissue in a mammal, and for facilitating transcitosis of a molecule through an endothelial cell barrier in a mammal, and composition for transporting a molecule via transcinosis through an endothelial cell barrier

Also Published As

Publication number Publication date
ES2296819T3 (en) 2008-05-01
US20040009912A1 (en) 2004-01-15
WO2002020031A3 (en) 2002-08-01
CY1107287T1 (en) 2012-11-21
PT1315515E (en) 2008-03-03
DK1315515T3 (en) 2008-04-14
DE10043457A1 (en) 2002-03-28
JP2004522696A (en) 2004-07-29
EP1315515A2 (en) 2003-06-04
EP1315515B1 (en) 2007-11-21
DE50113300D1 (en) 2008-01-03
WO2002020031A2 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
AU2002224927A1 (en) Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
AU5056300A (en) Devices and compounds for treating arterial restenosis
AU2002338336A1 (en) Epothilone derivatives and methods for making and using the same
AU2002360089A1 (en) Polymer derivatives for treating metals
AU2001219185A1 (en) 2-acylaminobenzimidazole derivatives for treating glaucoma
AU2002213466A1 (en) Compounds and methods for modulating ccr4 function
AU2002217866A1 (en) Geldanamycin derivatives useful for the treatment of cancer
AU3814599A (en) Use of erythropoietin for the treatment of haemochromatoses
AU2002213878A1 (en) Use of erythropoietin and the derivatives of the same for treating schizophrenia and related psychoses
AU5533300A (en) Novel 4-(2-oxodihydrooxadiazinylphenyl)amides and the use thereof for treating anemia
AU2002338989A1 (en) Substituted C-furan-2-yl-methylamine and C-thiophen-2-yl-methylamine derivatives
PT1698338E (en) S-methyl-dihydro-ziprasidone for the treatment of schizophrenia
AU2002216939A1 (en) Quinoline derivatives and their use as anti-epileptics
AU2001225523A1 (en) Novel arylpropionaldehyde derivatives and production and use of the same
AU2002217915A1 (en) Compositions and methods for diagnosing or treating psoriasis
AU2002229859A1 (en) Chemical derivatives and their use as anti-telomerase agent
AU2002227952A1 (en) Klainetin and derivatives thereof, method for their production and the use of the same
AU2002347393A1 (en) Susceptibility locus for schizophrenia
HU9900123D0 (en) 1-isothiazolidinone derivatives of azetidine-2-one, processes for the preparation thereof and use thereof
AU2001257164A1 (en) Methods and compositions for the diagnosis of schizophrenia
AU2002366756A1 (en) Use of benzofuroxan derivatives as antiplatelet agents
AU2002336130A1 (en) Pyridin-2-YL-Methlyamine derivatives for treating opioid dependence
AU2001259127A1 (en) Methods and composition for the diagnosis of schizophrenia
AU2001255597A1 (en) Methods and compositions for the diagnosis of schizophrenia
AU2001257180A1 (en) Methods and compositions for the diagnosis of schizophrenia